

Fig. 4. Effect of pertuzumab on epidermal growth factor receptor (EGFR) and HER3 phosphorylation and their downstream signaling pathways. The 11_18 and PC-9 cells were exposed to pertuzumab for 6 h and stimulated with either heregulin (HRG- α) or epidermal growth factor (EGF) for 10 min. Cell lysate were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotted for indicated antibodies. The intensities of bands were quantified by densitometer. (a) HRG- α -stimulated 11_18 cells. (b) EGF-stimulated 11_18 cells. (c) HRG- α -stimulated PC-9 cells. Data shown are representative of at least two independent experiments with similar results. MAPK, mitogen-activated protein kinase.

the phosphorylation level of the EGFR. Phosphorylation of MAPK and Akt was detected by the addition of HRG- α , but these were not inhibited by pertuzumab. These results suggest that pertuzumab is unable to affect HRG- α -stimulated phosphorylation of HER3 in the PC-9 cells.

To clarify the effect of pertuzumab on HER2 phosphorylation and HER2/HER3 heterodimer formation, cell lysates were immunoprecipitated with anti-HER2 antibody (Fig. 5a,b). HRG- α stimulation increased HER2/HER3 heterodimer formation in the 11_18 cells, and pertuzumab decreased HRG- α -stimulated heterodimer formation. EGFR/HER2 heterodimer formation could be barely detected by HRG- α stimulation because of slight expression of EGFR in the 11_18 cells. In the case of EGF stimulation, HER2/HER3 heterodimer was not increased in the 11_18 cells. These findings suggest that pertuzumab inhibits HER2/HER3 heterodimerization by HRG- α stimulation. The HRG- α -stimulated phosphorylation of HER2 was inhibited by pertuzumab in the 11_18 cells. In contrast, the EGF-stimulated phosphorylation of HER2 was not inhibited. These data suggest that pertuzumab inhibits HRG- α stimulated phosphorylation in 11_18 cells. In the PC-9 cells, HRG- α stimulated HER2/HER3 heterodimer formation could be detected without any ligand stimulation, and pertuzumab diminished HRG- α -stimulated heterodimer formation

(Fig. 5c). Phosphorylation of HER2 was increased by HRG- α stimulation, but not inhibited by pertuzumab in PC-9 cells. EGFR/HER2 heterodimer formation could be detected without any ligand stimulation, but pertuzumab did not affect it. Based on these results, it is speculated that the cell growth of the PC-9 cells is predominantly dependent on active EGFR signaling, and phosphorylation of HER3 is maintained by active mutant EGFR.

Discussion

Overexpression of HER3 was observed in the lung cancer cell lines and the HER3 was phosphorylated by the HER3 ligand in these cells. These results suggest that HER3 signaling is active in some types of lung cancer cells. Recently it was reported that high HER3 expression was associated with decreased survival.⁽¹⁷⁾ A relationship between lung cancer metastasis and the expression of HER3 as well as EGFR and HER2 has been reported.⁽¹⁸⁾ These bodies of evidence suggest that HER2/HER3 signaling is activated in a subpopulation of lung cancers and that HER2 and HER3 play an important role in the biological behavior of these lung cancers. Both HER2 and HER3 are therefore considered as a possible important target in the therapeutic strategy against lung cancer, just as they are in breast cancers.




Fig. 5. Effect of pertuzumab on heterodimer formation. The 11_18 and PC-9 cells were exposed to pertuzumab for 6 h and stimulated with either heregulin (HRG- α) or epidermal growth factor (EGF) for 10 min. Cell lysates were immunoprecipitated with anti-HER2 antibody, separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and blotted for indicated antibodies. The intensities of bands were quantified by densitometer. (a) HRG- α -stimulated 11_18 cells. (b) EGF-stimulated 11_18 cells. (c) HRG- α -stimulated PC-9 cells. Data shown are representative of at least two independent experiments with similar results.

HER3 lacks kinase activity because of several base substitutions in motifs that are essential to tyrosine kinase and heterodimerization with HER2 or EGFR is essential for its signal transduction. Therefore co-expression of HER3 and its partners are determinants for the cellular sensitivity against pertuzumab in cancer cells. The present results showed that HER2/HER3 heterodimers are detected by HRG- α stimulation and these data are consistent with previous reports.⁽¹⁹⁾ In contrast, the authors monitored the downstream phosphorylation signal, and demonstrated that HRG- α , but not EGF, phosphorylated Akt in the 11_18 cells. This finding allows us to speculate that HRG- α stimulation leads to Akt phosphorylation through HER2/HER3 heterodimerization.⁽²⁰⁻²²⁾

Recently, EGFR mutations have been reported in lung cancers and it was of great interest to clarify the relationship between the EGFR mutation and sensitivity to EGFR-targeted tyrosine kinase inhibitors.⁽²³⁻²⁵⁾ The PC-9 cells express the deletion mutant EGFR (delE746-A750 in exon 19 of EGFR),^(16,23,26,27) and their EGFR was constitutively phosphorylated under non-stimulated conditions (Fig. 3a). The authors speculate that the cell growth of the PC-9 cells is predominantly dependent on active EGFR signaling. In Fig. 3b, treatment with EGF and TGF- α seemed to decrease the phosphorylation of HER3 in PC-9 cells. Unfortunately, we could not conclusively explain this phenomenon. PC-9 cells express deletion EGFR and form EGFR homodimers in the absence of ligand stimulation. At the same time, phospho-HER3 was also detected under these conditions, suggesting that heterodimers of EGFR-HER3 were also formed. Ligand stimulation may alter the balance between homodimers and heterodimers, causing a reduction in HER3 phosphorylation, although there is not any evidence to support this hypothesis. In contrast, the phosphorylation of EGFR in the 11_18 cells that express a different type of mutant EGFR (L858R in exon 21 of EGFR),⁽²⁶⁾

was not constitutive. This finding may be explained by the differences between deletion mutant EGFR and L858R; constitutive active in the deletion mutant versus hyper-response to ligand stimulation in L858R.⁽²⁸⁾ Engelman *et al.* suggested that the mutant EGFR is used to couple HER3 in gefitinib-sensitive NSCLC cell lines.⁽²⁹⁾ The expression level of EGFR in the 11_18 cells was much lower than in the PC-9 cells, and a similar extent of HER3 expression was observed in these cell lines (Fig. 3a). The authors have demonstrated the differential inhibitory effect of pertuzumab against 11_18 and the PC-9 cells. Pertuzumab inhibited HER2/HER3 heterodimer formation and phosphorylation in the 11_18 cells, considering that mutant EGFR do not influence HER3 signals in the 11_18 cells. HER3 phosphorylation in the PC-9 cells was also increased by HRG- α stimulation. Although pertuzumab decreased HER2/HER3 heterodimer formation, it failed to inhibit HRG- α -stimulated HER3 phosphorylation, speculating that an active mutant EGFR transactivates HER3 in the PC-9 cells.

Several EGFR-targeted small inhibitors and antibodies have been under clinical evaluation in the treatment of lung cancer. An EGFR-targeted tyrosine kinase inhibitor, erlotinib, has been clinically applied as a second or third-line single agent therapy in NSCLC patients who have failed standard chemotherapy.⁽³⁰⁾ Anti-EGFR monoclonal antibodies such as cetuximab and ABX-EGF have been examined in a clinical study.⁽³¹⁾ In addition to EGFR, HER2 and HER3 are also considered as important targeting molecules in lung cancers. The present results indicated that pertuzumab effectively inhibited signaling within HER2 and HER3, and may thus be effective in lung cancers expressing HER2 and HER3. To confirm the pertuzumab-sensitive population of lung cancer cells, experiments using small interfering RNA for mutant EGFR will be necessary in future studies.

In conclusion, the authors have demonstrated that pertuzumab inhibits HRG- α -stimulated cell growth in lung cancer cells through the inhibition of HRG- α -stimulated HER3 signaling. It was further demonstrated that pertuzumab exerts an antiproliferative activity against lung cancer cells expressing HER2 and HER3. The next step will be to examine the clinical relevance of the

occurrence of heterodimer formation between HER2 and the other HER receptors in lung cancer.

Acknowledgment

This work was supported by funds for the Third Term Comprehensive 10-Year Strategy for Cancer Control.

References

- 1 Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol* 2001; 2: 127-37.
- 2 Tanner KG, Kyte J. Dimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factor. *J Biol Chem* 1999; 274: 35 985-90.
- 3 Riese DJ 2nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. *Bioessays* 1998; 20: 41-8.
- 4 Chang H, Riese DJ 2nd, Gilbert W, Stern DF, McMahan UJ. Ligands for ErbB-family receptors encoded by a neuregulin-like gene. *Nature* 1997; 387: 509-12.
- 5 Park OK, Schaefer TS, Nathans D. *In vitro* activation of Stat3 by epidermal growth factor receptor kinase. *Proc Natl Acad Sci USA* 1996; 93: 13 704-8.
- 6 Chang L, Karin M. Mammalian MAP kinase signalling cascades. *Nature* 2001; 410: 37-40.
- 7 Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. *Cancer Cell* 2004; 5: 317-28.
- 8 Agus DB, Gordon MS, Taylor C *et al*. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. *J Clin Oncol* 2005; 23: 2534-43.
- 9 Slamon DJ, Godolphin W, Jones LA *et al*. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 1989; 244: 707-12.
- 10 Naidu R, Yadav M, Nair S, Kuity MK. Expression of c-erbB3 protein in primary breast carcinomas. *Br J Cancer* 1998; 78: 1385-90.
- 11 Agus DB, Akita RW, Fox WD *et al*. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. *Cancer Cell* 2002; 2: 127-37.
- 12 Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. *Cancer Res* 2004; 64: 2343-6.
- 13 Nishio K, Arioka H, Ishida T *et al*. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. *Int J Cancer* 1995; 63: 688-93.
- 14 Kawamura-Akiyama Y, Kusaba H, Kanzawa F, Tamura T, Saijo N, Nishio K. Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines. *Lung Cancer* 2002; 38: 43-50.
- 15 Sato M, Takahashi K, Nagayama K *et al*. Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer. *Genes Chromosomes Cancer* 2005; 44: 405-14.
- 16 Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. *Int J Cancer* 2005; 116: 36-44.
- 17 Yi ES, Harclerode D, Gondo M *et al*. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. *Mod Pathol* 1997; 10: 142-8.
- 18 Muller-Tidow C, Diederichs S, Bulk E *et al*. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. *Cancer Res* 2005; 65: 1778-82.
- 19 Sliwkowski MX, Schaefer G, Akita RW *et al*. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. *J Biol Chem* 1994; 269: 14 661-5.
- 20 Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. *Embo J* 1997; 16: 1647-55.
- 21 Hellyer NJ, Kim MS, Koland JG. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. *J Biol Chem* 2001; 276: 42 153-61.
- 22 Jackson JG, St Clair P, Sliwkowski MX, Brattain MG. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. *Cancer Res* 2004; 64: 2601-9.
- 23 Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. *Cancer Res* 2004; 64: 9101-4.
- 24 Lynch TJ, Bell DW, Sordella R *et al*. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004; 350: 2129-39.
- 25 Paez JG, Janne PA, Lee JC *et al*. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004; 304: 1497-500.
- 26 Nagai Y, Miyazawa H, Huqun *et al*. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. *Cancer Res* 2005; 65: 7276-82.
- 27 Sakai K, Arao T, Shimoyama T *et al*. Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor. *Faseb J* 2005; 20: 311-13.
- 28 Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. *Science* 2004; 305: 1163-7.
- 29 Engelman JA, Janne PA, Mermel C *et al*. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. *Proc Natl Acad Sci USA* 2005; 102: 3788-93.
- 30 Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. *Oncologist* 2005; 10: 461-6.
- 31 Govindan R. Cetuximab in advanced non-small cell lung cancer. *Clin Cancer Res* 2004; 10: 4241-4s.

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

Hideharu Kimura,^{1,2} Kazuko Sakai,¹ Tokuzo Arai,^{1,3} Tatsu Shimoyama^{1,4} Tomohide Tamura⁵ and Kazuto Nishio^{1,3,6}

¹Shien-Laboratory, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045; ²Respiratory Medicine, Kanazawa University Hospital, Takara-machi 13-1, Kanazawa, Ishikawa, 920-8641; ³Department of Genome Biology, Kinki University School of Medicine, 377-2 Ohno-Higashi Osaka-Sayama, Osaka, 589-8511; ⁴Department of Chemotherapy, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677; ⁵Medical Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan

(Received February 1, 2007/Revised March 30, 2007/Accepted April 5, 2007/Online publication May 14, 2007)

Cetuximab (Erbix, IMC-C225) is a monoclonal antibody targeted to the epidermal growth factor receptor (EGFR). To clarify the mode of antitumor action of cetuximab, we examined antibody-dependent cellular cytotoxicity (ADCC) activity against several tumor cell lines expressing wild-type or mutant EGFR. ADCC activity and complement-dependent cytotoxicity activity were analyzed using the CytoTox 96 assay. ADCC activities correlated with the EGFR expression value ($R = 0.924$). ADCC activities were detected against all tumor cell lines, except K562 cells in a manner dependent on the cellular EGFR expression level, whereas complement-dependent cytotoxicity activity was not detected in any of the cell lines. The ADCC activity mediated by cetuximab was examined in HEK293 cells transfected with wild-type EGFR (293W) and a deletion mutant of EGFR (293D) in comparison with the mock transfectant (293M). ADCC activity was detected in 293W and 293D cells, in a cetuximab dose-dependent manner, but not in 293M cells (<10%). These results indicate that ADCC-dependent antitumor activity results from the degree of affinity of cetuximab for the extracellular domain of EGFR, independent of EGFR mutation status. These results suggest ADCC activity to be one of the modes of therapeutic action of cetuximab and to depend on EGFR expression on the tumor cell surface. (*Cancer Sci* 2007)

The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors that is abnormally activated in many malignancies. EGFR is frequently overexpressed or abnormally activated in tumors. EGFR overexpression correlates with a worse outcome.^(1,2) Early studies with anti-EGFR monoclonal antibodies (mAb) were shown to inhibit the growth of cancer cells bearing EGFR.⁽³⁾

Cetuximab (IMC-225, Erbitux) is a recombinant, human-murine chimeric mAb that is produced in mammalian (murine myeloma) cell culture and targeted specifically to EGFR. Cetuximab is composed of a murine Fv (EGFR-binding) lesion and a human IgG1 heavy and κ light chain Fc (constant) region. *In vitro* studies have shown that cetuximab competes with endogenous ligands to bind with the external domain of EGFR. Cetuximab binds to EGFR with 10-fold higher affinity than endogenous ligands (0.1–0.2 nM cetuximab vs 1 nM epidermal growth factor [EGF] or transforming growth factor (TGF)- α , respectively).⁽⁴⁾ Cetuximab has shown promising preclinical and clinical activity in a variety of tumor types.⁽⁵⁾

The anti-tumor strategy is to direct mAb to the ligand-binding extracellular domain and to prevent ligand binding and ligand-dependent receptor inhibition. The use of humanized murine-human chimeric mAb of the IgG1 subtype is now well established for the treatment of human cancers. Treatment of advanced breast cancer with human epidermal growth factor receptor type 2 (HER-2)-specific trastuzumab (Herceptin) and of follicular

non-Hodgkin B-cell lymphoma with CD20-specific rituximab (Mabthera, Rituxan) has been shown to increase overall survival. Human IgG1 is thought to eliminate tumor cells via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), depending on the target, and also by direct pro-apoptotic signaling or growth factor receptor antagonism. Clynes *et al.* suggested that ADCC is a major *in vivo* mechanism of IgG1 action.⁽⁶⁾ Recently, several mAb, including trastuzumab, which act predominantly via ADCC and CDC have been approved for the treatment of cancer patients. These include chimeric IgG1 mAb rituximab binding to the B-cell differentiation antigen CD20 for the treatment of B-cell lymphomas,⁽⁷⁾ humanized IgG1 mAb trastuzumab targeting HER-2 overexpressed in a subgroup of breast cancers,⁽⁸⁾ and humanized IgG1 alemtuzumab (Campath) targeting the differentiation antigen CD52 for the treatment of B-cell chronic lymphocytic leukemia.⁽⁹⁾

We hypothesized that ADCC is a possible mode of action of cetuximab against EGFR-expressing tumors. The present study was designed to clarify the role of cetuximab in ADCC and CDC activity, and to evaluate the relationship between EGFR expression status and cetuximab-mediated ADCC and CDC activity.

Methods

Cell lines and cultures. A human leukemia cell line (K562), a non-small cell lung cancer (NSCLC) cell line (A549) and a human embryonic kidney cell line (HEK293) were obtained from the American Type Culture Collection (Manassas, VA, USA). Human NSCLC cell lines A431, PC-9 and PC-14 were obtained from Tokyo Medical University (Tokyo, Japan). Human NSCLC cell lines Ma-1 and 11_18 were obtained from the National Cancer Center Research Institute (Tokyo, Japan). PC-9 and Ma-1 are known to contain E746_A750del, and 11_18 is known to contain L858R in tyrosine kinase domains of EGFR. The other cell lines are known to have wild-type EGFR. K562, HEK293, A431, PC-9, PC-14, Ma-1 and 11_18 cells were cultured in RPMI-1640 (Sigma, St Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco BRL, Grand Island, NY, USA). A549 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) with 10% heat-inactivated FBS.

Plasmid construction and transfection. Construction of the mock expression plasmid vector (empty vector) and of the wild-type EGFR and 15-bp deletion EGFR (E746-A750del type deletion)

⁶To whom correspondence should be addressed. E-mail: knishio@med.kindai.ac.jp

vectors, both of which possess the same deletion site as that observed in PC-9 cells, have been described elsewhere.⁽¹⁰⁾ The plasmids were transfected into HEK293 cells and the transfectants were selected with Zeosin (Sigma). The stable transfectants (pooled cultures) of the empty vector, wild-type EGFR and its deletion mutant were designated 293M, 293W and 293D cells, respectively.

Compound. The mAb anti-EGFR cetuximab (IMC-225, Erbitux) was kindly provided by Bristol Myers Squibb (New York, NY, USA).

Analysis of EGFR expression on the cell surface. Cell surface expression of EGFR in tumor cell lines was quantified using a flow cytometric system (BD LSR; Becton-Dickinson, San Jose, CA, USA). The binding of cetuximab to tumor cell lines was titrated using FACS analysis. Cetuximab and another anti-EGFR mAb (R-1, sc-101; Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as the primary antibodies. Then, 1×10^6 tumor cells were incubated with 1 $\mu\text{g}/\text{mL}$ cetuximab in 1% bovine serum albumin in phosphate-buffered saline (PBS) for 30 min at room temperature. After the first reactions, the cell surface was stained with 10 $\mu\text{g}/\text{mL}$ fluorescein-conjugated antihuman IgG (Vector, Burlingame, CA, USA) for 45 min at room temperature in the dark. After the second reactions, the tumor cells were resuspended in 1 mL PBS. For analysis using the anti-EGFR mAb, 1 μg EGFR mAb per 1×10^6 tumor cells was used as the primary antibody. The secondary antibody was 10 $\mu\text{g}/\text{mL}$ fluorescein-conjugated antimouse IgG (Vector). A minimum of 2×10^4 cells were analyzed by flow cytometry. Control experiments were carried out in the absence of primary antibodies. Data were analyzed with CellQuest software and the modifying program (Beckton Dickinson, CA, USA). The magnitude of surface expression of these proteins was indicated by the mean fluorescence intensity (MFI) of positively stained cells. The expression values were calculated as follows:

$$\text{Expression value} = \frac{\text{MFI of positively stained cells}}{\text{MFI of control cells}}$$

The correlation between the expression of R-1-combined EGFR and that of cetuximab-combined EGFR were calculated using simple regression analysis.

Cytotoxicity assays. ADCC and CDC were examined using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI). For quantification of ADCC activity, peripheral blood mononuclear cells were isolated from healthy volunteers with Lymphocyte Separation Medium (Cappel, Aurora, OH, USA) and used as effector cells. The target cells were suspended in RPMI medium without FBS and plated in a 96-well U-bottom microtiter plate at 5×10^3 cells/well. Cetuximab was added in triplicate to the individual wells at various concentrations from 0.001 to 10 $\mu\text{g}/\text{mL}$ and effector cells were added at an effector: target cell ratio of 10:1. For quantification of CDC activity, human serum from a healthy volunteer was obtained as a complement source. To yield a 1:3 final dilution, 50 μL serum was added. The plates were incubated for 4 h at 37°C, and the absorbance of the supernatants at 490 nm was recorded to determine the release of lactate dehydrogenase. The average of absorbance values for the culture medium background was subtracted from experimental release (A), target cell spontaneous release (B), effector cell spontaneous release (C) and target cell maximum release (D). The specific cytolysis percentage was calculated using the following formula:

$$\text{Cytotoxicity (\%)} = \frac{(A - B - C)/(D - B) \times 100}{1}$$

The correlation between the expression of cetuximab-combined EGFR and ADCC activity was calculated using a simple regression analysis.

Growth-inhibition assay. We used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to evaluate

the cytotoxicity of various drug concentrations. Two hundred microliters of an exponentially growing cell suspension was seeded in a 96-well microtiter plate, and cetuximab-containing solution was added at various concentrations (from 0.001 to 100 $\mu\text{g}/\text{mL}$). Each experiment was carried out in triplicate for each drug concentration and independently three times.

Growth inhibitory assay for the combination of gefitinib and cetuximab-mediated ADCC in the PC-9 cell line. We analyzed the growth inhibitory effect of the combination of gefitinib and cetuximab-mediated ADCC in the PC-9 cell line using the MTT assay. Two hundred microliters containing 1000 PC-9 cells, and various concentrations of gefitinib, were seeded in a 96-well microtiter plate. Then, 10 μL of cetuximab-containing solutions of various concentrations (from 0.1 to 10 $\mu\text{g}/\text{mL}$) and 20 000 effector cells were added.

Western blotting. PC-9, PC-14 and A549 cell lines were seeded in cell culture plates at a density of 6.0×10^5 cells/plate and allowed to grow overnight in appropriate maintenance cell culture media for each cell line containing 10% heat-inactivated FBS. The media were then replaced with RPMI-1640 (Sigma) (PC-9 and PC-14) or DMEM without FBS, with or without cetuximab (10 and 100 $\mu\text{g}/\text{mL}$). The cells were incubated for a further 24 h and stimulated or not stimulated with EGF (100 ng/mL) under serum starvation conditions. Cells were washed with ice-cold PBS and scraped immediately after adding 50 μL of M-PER mammalian protein extraction reagent (Pierce Biotechnology, Rockford, IL, USA). The protein extracts were separated by electrophoresis on 7.5% sodium dodecylsulfate-polyacrylamide gels and transferred to nitrocellulose membranes by electroblotting. The membranes were probed with a mouse monoclonal antibody against EGFR (Transduction Laboratory, San Diego, CA, USA), and phosphor-EGFR (specific for Tyr1068), Akt, phosphor-Akt, p44/42 MAPK and phosphor-p44/42 MAPK antibodies (Cell Signaling Technology, Beverly, MA, USA) as primary antibodies, followed by a horseradish peroxidase-conjugated secondary antibody. The bands were visualized with an electrochemiluminescence reagent (ECL; Amersham, Piscataway, NJ, USA).

Results

Binding properties of cetuximab to tumor cell lines expressing EGFR. The A431 cells expressed a high level of EGFR on their surfaces. Cell surface EGFR expression values of the PC-9, PC-14, A549, Ma-1 and 11_18 cell lines were lower than that of A431. The MFI for the K562 cells was less than 10 (Table 1). A good

Table 1. Epidermal growth factor receptor (EGFR) expression values and antibody-dependent cellular cytotoxicity (ADCC) activity

Cell line	EGFR expression (R-1)	EGFR expression (cetuximab)	ADCC (%)
A431	286.2 \pm 13.7	318.9 \pm 98.2	30.7
PC-9	9.7 \pm 6.2	20.1 \pm 10.2	20.1
PC-14	17.6 \pm 1.5	42.2 \pm 8.6	26.8
A549	9.1 \pm 1.9	19.1 \pm 6.2	24.2
Ma-1	13.8 \pm 1.4	27.5 \pm 2.9	22.3
11_18	6.1 \pm 0.6	12.6 \pm 1.1	15.5
K562	1.1 \pm 0.4	2.8 \pm 1.6	7.0
293M	3.7 \pm 1.6	8.6 \pm 3.2	8.2
293W	40.19 \pm 6.2	39.73 \pm 6.2	16.3
293D	55.21 \pm 21.9	53.04 \pm 8.2	18.9

Expression values and ADCC activity were calculated as described in the Materials and Methods section. The mean of expression values from three different experiments and standard deviations are shown. The values for cetuximab-combined EGFR expression are shown for a concentration of 1 $\mu\text{g}/\text{mL}$.




Fig. 1. Epidermal growth factor receptor (EGFR) expression and cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity in the tumor cell lines. (a) Correlation between the expression of cetuximab-combined EGFR and R-1-combined EGFR. The values for cetuximab-combined EGFR expression are shown for a concentration of 1 µg/mL. The correlation coefficient between the results of these assays was 0.999. (b) Cetuximab-mediated ADCC activity in tumor cell lines at concentrations ranging from 0.001 to 10 µg/mL was determined using the CytoTox 96 Non-Radioactive Cytotoxicity Assay. (c) Correlation between expression values of cetuximab-combined EGFR and ADCC activity in the seven tumor cell lines. The values for cetuximab-combined EGFR expression and cetuximab-mediated ADCC activity are shown for a concentration of 1 µg/mL. The correlation coefficient between the results of these assays was 0.924. (d) Correlation between expression values of cetuximab-combined EGFR and ADCC activity in transfected HEK293 cell lines. The correlation coefficient between the results of these assays was 0.952.

correlation was observed between the binding of cetuximab and R-1 antibody with a correlation coefficient of 0.999 ($P < 0.001$; Fig. 1a).

ADCC and CDC activities in tumor cell lines. ADCC activities of cetuximab were detected in all tumor cell lines except K562 (Table 1; Fig. 1b). In the K562 cells, % ADCC activities were lower than 10% at all concentrations of cetuximab examined (from 0.001 to 10 µg/mL). ADCC activity mediated by cetuximab was highly correlated with the binding values of cetuximab to cells expressing EGFR ($R = 0.924$, $P = 0.003$; Fig. 1c). CDC activity was not detected in any of the cell lines in the cetuximab concentration range from 0.001 to 10 µg/mL.

Direct growth inhibitory effect of cetuximab on tumor cell lines. Cetuximab showed no growth inhibitory effect in any of the cell lines examined, regardless of EGFR expression levels. Even the highest concentration of cetuximab (100 µg/mL) did not inhibit growth in any of the cell lines (Fig. 2).

ADCC activities of cetuximab against the cells transfected with wild-type and mutant EGFR. EGFR expression was detected in 293W and 293D cells, but not in 293M cells (Table 1). The

ADCC activity mediated by cetuximab in 293W and 293D cells was dose dependent. In contrast, ADCC activities in 293M cells were <10% at all concentrations of cetuximab tested (0.001–10 µg/mL). There was a good correlation between the ADCC activities and the levels of cetuximab binding to EGFR in the cells ($R = 0.996$, $P = 0.055$; Fig. 1d). These results indicate that ADCC depends on the level of cetuximab binding to EGFR, but not the mutation status of the EGFR tyrosine kinase domains.

Direct growth inhibitory effect of the combination of gefitinib and cetuximab-mediated ADCC in the PC-9 cell line. The growth inhibitory effect in the PC-9 cell line was shown by effector cells at a gefitinib exposure exceeding 0.01 µM and was concentration dependent (Fig. 3). When cetuximab was added, growth was inhibited in a cetuximab concentration-dependent manner. An additive growth inhibitory effect was recognized between 0 and 0.01 µM of gefitinib. This additive growth inhibitory effect could not be evaluated at concentrations between 0.1 and 1.0 µM because of the strong inhibitory effect of gefitinib alone.

Effect of cetuximab on phosphorylation of EGFR and its downstream signaling molecules in NSCLC cells. Phosphorylation of EGFR




Fig. 2. Growth inhibitory effect of cetuximab on non-small cell lung cancer cell lines: (a) A431; (b) PC-9; (c) PC-14; (d) A549; (e) Ma-1; (f) 11_18; and (g) K562. Cell growth was not inhibited at any concentration, even a high concentration (10 µg/mL). The figure shows the dose-dependent growth inhibitory effect of gefitinib with various concentrations of cetuximab (0–10 µg/mL). Results are expressed as percentages of the untreated control value. The data shown are the mean + SD values from triplicate experiments.




Fig. 3. Growth inhibitory effects of combining gefitinib and cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC). The figure shows dose-dependent growth inhibitory effects of gefitinib with various concentrations of cetuximab (solid circle, 0 µg/mL; solid square, 0.1 µg/mL; open circle, 1.0 µg/mL; solid triangle, 10 µg/mL). Results are expressed as a percentage of the untreated control value. The data shown represent the median values of triplicate experiments.

was strongly expressed in PC-9 regardless of EGF treatment, and the phosphorylation of EGFR continued the strong expression during cetuximab treatment. Phosphorylation of EGFR was slightly expressed in PC-14 and A549 without EGF treatment, but the phosphorylation of EGFR was enhanced by the EGF treatment. Although the enhancement of phosphorylation was inhibited dose dependently by cetuximab, the phosphorylation

was not completely inhibited at the highest concentration (10 µg/mL) of cetuximab. Phosphorylation of 44/42 MAPK and Akt was increased in all cell lines compared with the absence of EGF treatment. Although the increase in phosphorylation was diminished by adding cetuximab, phosphorylation was not completely inhibited at the highest concentration (10 µg/mL) of cetuximab (Fig. 4).

Discussion

Antibody therapies are a major approach in the treatment of various cancer types. Herein, we focused on the ADCC activity mediated by cetuximab against human lung cancer cells expressing wild-type or mutant EGFR. Neither CDC nor direct growth inhibition mediated by cetuximab was detectable in our experiments.

Direct growth inhibition, ADCC and CDC mediated by antibodies are the modes of action of antibody therapies. We previously demonstrated that ADCC is the major mode of action of trastuzumab in breast cancer cell lines, even when used in combination with cisplatin.⁽¹¹⁾ Cisplatin did not affect ADCC activity at the concentration for combined use *in vitro*. Clinical efficacies of cetuximab for various types of cancers have been demonstrated in many clinical studies using combinations with cytotoxic agents including cisplatin. Thus, ADCC is considered to be an important factor governing the efficacy of cetuximab.

Mukohara *et al.* reported that EGFR mutations in NSCLC cells are not associated with sensitivity to cetuximab *in vitro*.⁽¹²⁾ They focused on the direct growth inhibitory effect of cetuximab against lung cancer cells. We previously demonstrated that PC-9 and 293 cells transfected with E746_A750del EGFR are




Fig. 4. Effects of cetuximab on phosphorylation of epidermal growth factor receptor (EGFR), Akt and p44/42 MAPK in non-small cell lung cancer cell lines. (a) EGFR mutant cell line PC-9 (with the E746_A750del mutation). (b) EGFR wild-type cell line PC-14. (c) EGFR wild-type cell line A549. Cells were treated with cetuximab at the indicated concentrations for 24 h. Immunoblots of cellular protein were analyzed for phosphorylated and total EGFR, p44/42 MAPK and Akt. The experiments were repeated at least twice.

hypersensitive to EGFR-tyrosine kinase inhibitors.⁽¹⁰⁾ In contrast, we have demonstrated that ADCC activity mediated by cetuximab is not affected by EGFR mutation status in lung cancer cells or in 293 cells transfected with EGFR. Taken together, these observations indicate that cetuximab exerts its antitumor effects against human lung cancer cells independently of EGFR mutation status.

ADCC activity mediated by cetuximab has been demonstrated against 293 cells transfected with wild-type and mutated EGFR. Higher ADCC activity against 293D cells compared with 293W cells was observed with cetuximab exposure (Fig. 1d; Table 1). However, ADCC was correlated with EGFR expression levels in these transfectants. The activity appears to depend on expression levels but not mutation status.

Approximately 30 mutations of EGFR have been reported in lung cancer.⁽¹³⁻¹⁶⁾ ADCC activity against PC-9 cells with E746_A750del in exon 19, one of the common mutations, has been demonstrated herein. We also examined ADCC activity against another human lung cancer cell line, 11_18,⁽¹⁷⁾ with L858R in exon 21, which is another common mutation. Our results showed a strong positive correlation between ADCC activity and EGFR expression level, and that the impact on ADCC activity did not depend on the site of EGFR mutations.

Cetuximab is a chimeric antibody against the extracellular domain of EGFR. Other antitumor anti-EGFR antibodies currently under investigation clinically include humanized antibodies.⁽¹⁸⁾ It remains unknown whether humanized and chimeric antibodies

exert ADCC activity against lung cancer differentially, and this awaits future investigation.

Some investigators have reported on the predictive factor and enhancement of ADCC activity mediated by certain mAb other than cetuximab.⁽¹⁹⁻²²⁾ Important ADCC-mediating effector cells that express receptors against the Fc region of IgG include monocytes and macrophages (FcγRI, IIa and IIb), granulocytes (FcγRII) and natural killer cells (FcγRIII).⁽¹⁹⁾ One group of researchers demonstrated single nucleotide polymorphisms of FcγRIII in individual patients correlating with rituximab-dependent ADCC activity and the clinical response to rituximab.⁽²⁰⁾ Carson *et al.* demonstrated that the natural killer cell-mediated ADCC activity of breast cancer cell lines expressing HER2/*neu*, in the presence of trastuzumab, was markedly enhanced following stimulation with interleukin 2 and proposed the concurrent use of trastuzumab and interleukin-2 therapy in patients with cancers expressing HER2/*neu*.⁽²¹⁾ However, from the view point of mAb but not effector cells, lack of fucosylation of the antibodies affects ADCC enhancement.⁽²²⁾ Whether or not these factors enhance cetuximab-mediated ADCC activity warrants further examination.

We showed additional growth inhibition by gefitinib and cetuximab in PC-9 cells. PC-9 cells had a deletional mutation in exon 19 of *EGFR* and hyper-responsiveness to gefitinib. We think that cetuximab-mediated ADCC increased the growth inhibition-independent response to gefitinib. The ADCC activity could not be evaluated at higher concentrations of gefitinib (>0.1 µM) because PC-9 cells were sufficiently inhibited at the higher concentrations. Additionally, we showed that some phosphorylations downstream of EGFR in NSCLC cell lines were mediated by cetuximab, although cetuximab had no growth inhibitory effect on the cell lines. We think that cetuximab-combined EGFR inhibits binding of EGFR and its ligands, such as EGF, and that phosphorylation downstream of EGFR is inhibited as a consequence of the addition of cetuximab. We have shown that phosphorylation of 44/42 MAPK and Akt in NSCLC cell lines was increased by EGF treatment and decreased by then adding cetuximab. Phosphorylation of EGFR in PC-14 and A549 cells was decreased with the addition of cetuximab, as in the 44/42 MAPK and Akt cell lines. Phosphorylation of EGFR in PC-9 cells was strongly increased without ligands under serum starvation conditions and was not decreased by cetuximab. Phosphorylation that was independent of ligand binding to EGFR seem not to be controlled by cetuximab.

These results conclude that cetuximab has ADCC activity against tumor cells with EGFR expression, and ADCC activity depends on the degree of EGFR expression on tumor cell surfaces, additionally leading us to believe that cetuximab treatment has clinical activity in EGFR-expressing tumor cells via cetuximab-mediated ADCC.

Acknowledgments

H. Kimura received support as an Awardee of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research (Japan) for the 3rd Term Comprehensive 10-Year-Strategy for Cancer Control.

References

- Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit Rev Oncol Hematol* 1995; 19: 183-232.
- Selvaggi G, Novello S, Torri V *et al.* Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. *Ann Oncol* 2004; 15: 28-32.
- Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. *Clin Cancer Res* 1997; 3: 2703-7.
- de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. *Trends Mol Med* 2002; 8: S19-26.
- Mendelson J. Blockade of receptors for growth factors: an anticancer therapy - the fourth annual Joseph H Burchenal American Association of

Cancer Research Clinical Research Award Lecture. *Clin Cancer Res* 2000; 6: 747-53.

- Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate *in vivo* cytotoxicity against tumor targets. *Nat Med* 2000; 6: 443-6.
- Grillo-Lopez AJ, White CA, Varns C *et al.* Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. *Semin Oncol* 1999; 26: 66-73.
- Vogel C, Cobleigh MA, Tripathy D *et al.* First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: a preliminary report. *Eur J Cancer* 2001; 37: S25-9.
- Hale G, Zhang MJ, Bunjes D *et al.* Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. *Blood* 1998; 92: 4581-90.

- 10 Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. *Cancer Res* 2004; 64: 9101-4.
- 11 Naruse I, Fukumoto H, Saijo N, Nishio K. Enhanced anti-tumor effect of trastuzumab in combination with cisplatin. *Jpn J Cancer Res* 2003; 93: 574-81.
- 12 Mukohara T, Engelman JA, Hanna NH *et al*. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. *J Natl Cancer Inst* 2005; 97: 1185-94.
- 13 Lynch TJ, Bell DW, Sordella R *et al*. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004; 350: 2129-39.
- 14 Paez JG, Janne PA, Lee JC *et al*. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004; 304: 1497-500.
- 15 Pao W, Miller V, Zakowski M *et al*. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci USA* 2004; 101: 13 306-11.
- 16 Shigematsu H, Lin L, Takahashi T *et al*. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* 2005; 97: 339-46.
- 17 Nagai Y, Miyazawa H, Tanaka T *et al*. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. *Cancer Res* 2005; 65: 7276-82.
- 18 Bianco R, Daniele G, Ciardiello F, Tortora G. Monoclonal antibodies targeting the epidermal growth factor receptor. *Curr Drug Targets* 2005; 6: 275-87.
- 19 Graziano RF, Fanger MW. Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells. *J Immunol* 1987; 139: 3536-41.
- 20 Dall'Ozzo S, Tartas S, Paintaud G *et al*. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. *Cancer Res* 2004; 64: 4664-9.
- 21 Carson WE, Parihar R, Lindemann MJ *et al*. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. *Eur J Immunol* 2001; 31: 3016-25.
- 22 Shinkawa T, Nakamura K, Yamane N *et al*. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. *J Biol Chem* 2003; 278: 3466-73.

AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor

Masayuki Takeda,^{1,3} Tokuzo Arai,^{1,4} Hideyuki Yokote,^{1,4} Teruo Komatsu,⁵ Kazuyoshi Yanagihara,⁵ Hiroki Sasaki,⁶ Yasuhide Yamada,² Tomohide Tamura,² Kazuya Fukuoka,⁷ Hiroshi Kimura,³ Nagahiro Saijo,² and Kazuto Nishio^{1,4}

Abstract Purpose: AZD2171 is an oral, highly potent, and selective vascular endothelial growth factor signaling inhibitor that inhibits all vascular endothelial growth factor receptor tyrosine kinases. The purpose of this study was to investigate the activity of AZD2171 in gastric cancer.

Experimental Design: We examined the antitumor effect of AZD2171 on the eight gastric cancer cell lines *in vitro* and *in vivo*.

Results: AZD2171 directly inhibited the growth of two gastric cancer cell lines (KATO-III and OCUM2M), with an IC_{50} of 0.15 and 0.37 $\mu\text{mol/L}$, respectively, more potently than the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib. Reverse transcription-PCR experiments and immunoblotting revealed that sensitive cell lines dominantly expressed COOH terminus-truncated fibroblast growth factor receptor 2 (FGFR2) splicing variants that were constitutively phosphorylated and spontaneously dimerized. AZD2171 completely inhibited the phosphorylation of FGFR2 and downstream signaling proteins (FRS2, AKT, and mitogen-activated protein kinase) in sensitive cell lines at a 10-fold lower concentration (0.1 $\mu\text{mol/L}$) than in the other cell lines. An *in vitro* kinase assay showed that AZD2171 inhibited kinase activity of immunoprecipitated FGFR2 with submicromolar K_i values ($\sim 0.05 \mu\text{mol/L}$). Finally, we assessed the antitumor activity of AZD2171 in human gastric tumor xenograft models in mice. Oral administration of AZD2171 (1.5 or 6 mg/kg/d) significantly and dose-dependently inhibited tumor growth in mice bearing KATO-III and OCUM2M tumor xenografts.

Conclusions: AZD2171 exerted potent antitumor activity against gastric cancer xenografts over-expressing FGFR2. The results of these preclinical studies indicate that AZD2171 may provide clinical benefit in patients with certain types of gastric cancer.

Various anticancer therapies for gastric cancer have been investigated over the past two decades. Despite intensive studies, the prognosis for patients with unresectable advanced or recurrent gastric cancer remains poor (1, 2), and new therapeutic modalities are needed.

Authors' Affiliations: ¹Shien Lab and ²Medical Oncology, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan; ³Second Department of Internal Medicine, Nara Medical University; ⁴Department of Genome Biology, Kinki University School of Medicine, Ohno-higashi, Osaka-Sayama, Osaka, Japan; and ⁵Central Animal Lab and ⁶Genetic Division, National Cancer Center Research Institute; and ⁷Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

Received 11/16/06; revised 1/29/07; accepted 2/27/07.

Grant support: Third-Term Comprehensive 10-Year Strategy for Cancer Control and program for promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation and Japan Health Sciences Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: M. Takeda and T. Arai are the recipient of a Research Resident Fellowship from the Foundation of Promotion of Cancer Research in Japan.

Requests for reprints: Kazuto Nishio, Department of Genome Biology, Kinki University School of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan. Fax: 81-72-366-0206; E-mail: knishio@med.kindai.ac.jp.

© 2007 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-06-2743

Fibroblast growth factors (FGF) and their signaling receptors have been found to be associated with multiple biological activities, including proliferation, differentiation, motility, and transforming activities (3–5). The *K-sam* gene was first identified as an amplified gene in human gastric cancer cell line KATO-III (6, 7), and its product was later found to be identical to the bacteria-expressed kinase, or keratinocyte growth factor receptor (KGFR), and FGF receptor 2 (FGFR2). FGFR2/KGFR/K-sam is preferentially amplified in poorly differentiated types of gastric cancers with a malignant phenotype, and its protein expression was detected by immunohistochemical staining from 20 of 38 cases of the undifferentiated type of advanced stomach cancer (8, 9). Thus, FGFR2 signaling may be as a promising molecular target for gastric cancer.

AZD2171 is a potent, ATP-competitive small molecule that inhibits all vascular endothelial growth factor receptors [VEGFR-1, VEGFR-2 (also known as KDR), and VEGFR-3]. *In vitro* studies have shown that recombinant VEGFR-2 tyrosine kinase activity was potently inhibited by AZD2171 ($IC_{50} < 1 \text{ nmol/L}$; ref. 10). AZD2171 also showed potent activity versus VEGFR-1 and VEGFR-3 (IC_{50} , 5 and $\leq 3 \text{ nmol/L}$, respectively). VEGF-stimulated proliferation and VEGFR-2 phosphorylation of human umbilical vascular endothelial cells

was inhibited by AZD2171 (IC₅₀, 0.4 and 0.5 nmol/L, respectively). In *in vivo* studies, inhibition of VEGFR-2 signaling by AZD2171 reduced microvessel density and dose-dependently inhibited the growth of various human tumor xenografts (colon, lung, prostate, breast, and ovary; ref. 10). These data are consistent with potent inhibition of VEGF signaling, angiogenesis, neovascular survival, and tumor growth. On the other hand, because it was known that AZD2171 also possesses additional activity against FGFR1 (IC₅₀, 26 nmol/L; ref. 10), we hypothesized that AZD2171 may exhibit the additional anticancer activity against FGFR-overexpressing gastric cancer cells.

Our previous studies showed significant activities of the dual VEGFR-2 and epidermal growth factor receptor inhibitor ZD6474 against poorly differentiated gastric cancer (11) and non-small-cell lung cancer with epidermal growth factor receptor mutations (12, 13), both *in vitro* and *in vivo*. Based on these findings, we proceeded to investigate the anticancer activity of AZD2171 in preclinical models (gastric cell lines and xenografts).

Materials and Methods

Anticancer agents. AZD2171 and gefitinib (Iressa) were provided by AstraZeneca. AZD2171 and gefitinib were dissolved in DMSO for the *in vitro* experiments, and AZD2171 was suspended in 1% (w/v) aqueous polysorbate 80 and administered in a dose of 0.1 mL/10 g per body weight in the *in vivo* experiments.

Cell culture. Human gastric cancer cell lines 44As3, 58As1, OKAJIMA, OCUM2M, KATO-III, MKN-1, MKN-28, and MKN-74 were maintained in RPMI 1640 (Sigma) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies) and penicillin-streptomycin.

Established highly tumorigenic cell line. Signet ring cell gastric carcinoma cell line KATO-III was gift from Dr. M. Sekiguchi (University of Tokyo, Tokyo, Japan). All of the presented *in vitro* experiments were done using the KATOIII cell line. We conducted a preliminary experiment to compare the cellular characteristics of TU-KATO-III cells and KATOIII cells, and the results revealed that a high expression level of FGFR2 and high sensitivity to AZD2171 were still maintained in the TU-KATO-III cells (data not shown). KATO-III did not show tumorigenicity following repeated implantation of the cultured cells into BALB/c nude mice. Following s.c. inoculation into nonobese diabetic/severe combined immunodeficient mice, 80% to 100% of the KATO-III cells caused the formation of tumor. Following this result, we cultured the cancer cells isolated from the tumor of mice that developed 2 to 3 months following the implantation of KATO-III cells and attempted s.c. injection into nude mice, in turn, of the incubated cells. This sequence of manipulations was repeated for seven cycles in an attempt to reliably isolate cell lines that would have higher potential to undergo tumor formation over short periods of time. In this way, we obtained a cell line (TU-kato-III) from KATO-III cells that possessed a high tumorigenic potential.

In vitro growth inhibition assay. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to evaluate the growth-inhibitory effect of AZD2171. Cell suspensions (180 μ L) were seeded into each well of 96-well microculture plate and incubated in 10% fetal bovine serum medium for 24 h. The cells were exposed to AZD2171 or gefitinib at concentrations ranging from 4 nmol/L to 80 μ mol/L and cultured at 37°C in a humidified atmosphere for 72 h. After the culture period, 20 μ L 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reagent was added, and the plates were incubated for 4 h. After centrifugation, the culture medium was




Fig. 1. *A*, *in vitro* growth-inhibitory effect of AZD2171 and gefitinib on eight gastric cancer cell lines. AZD2171 had a growth-inhibitory effect on KATO-III cells and OCUM2M cells (IC₅₀, 0.15 and 0.37 μ mol/L, respectively). Columns, mean IC₅₀ of each compound from three independent experiments; bars, SD. □, IC₅₀ of gefitinib; ■, IC₅₀ of AZD2171. *B*, the mRNA expression levels of VEGFRs, FGFRs, and c-KIT in gastric cancer cell lines were determined by reverse transcription-PCR. Human umbilical vascular endothelial cells were used as the positive control for the VEGFRs. No mRNA expression of VEGFRs or c-KIT was detected by reverse transcription-PCR in both sensitive cell lines, but FGFR2 was strongly detected; however, little faint or none was detected in the other cell lines.

discarded, and wells were filled with DMSO. The absorbance of the cultures at 562 nmol/L was measured using Delta-soft on a Macintosh computer (Apple) interfaced to a Bio-Tek Microplate Reader EL-340 (BioMatellics). This experiment was done in triplicate.

Reverse-transcription PCR. Using a GeneAmp RNA-PCR kit (Applied Biosystems), 5 μ g of total RNA from each cultured cell line was converted to cDNA. The PCR amplification procedure consisted of 28 to 35 cycles (95°C for 45 s, 62°C for 45 s, and 72°C for 60 s) followed by incubation at 72°C for 7 min, and the bands were visualized by ethidium bromide staining. The following primers were used for the PCR: human-specific β -actin, forward 5-GGAAATCGTGCGTGACATT-3 and reverse 5-CATCTGCTGGAAGGTGGACAG-3; VEGFR-1, forward 5-TAGCGTACCAGCAGCGAAAGC-3 and reverse 5-CCTTCTTTGGTCTCTGTGC-3; VEGFR-2, forward 5-CAGACGGACAGTGGTATGGTTC-3 and reverse 5-ACCTGCTGGTGGAAAGAACAAC-3; VEGFR-3, forward 5-AGCCATTCATCAACAAGCCT-3 and reverse 5-GGCAACAGCTGGATGTCATA-3; c-KIT, forward 5-GCCACAATA-GATTGTTATT-3 and reverse 5-AGCATCITTACAGCCAGATC-3; FGFR1, forward 5-GGAGGATCGAGCTCACTCGTGG-3 and reverse

5-CGGAGAAGTACGTGGTGTAC-3; FGFR2, forward 5-CAGTAGACTGTAGACAGTAA-3 and reverse 5-CCGGTGAAGGCGATCGCTCACA-3; FGFR3, forward 5-GGTCGAAGGATCGCACAGGCTG-3 and reverse 5-AGCAGCTTCTGTCCATCCGCT-3; and FGFR4, forward 5-CCGCTAGAGATTGCCAGCTTC-3 and reverse 5-AGGCCTGTCATCCTTAAGCA-3.

Real-time reverse transcription-PCR. Real-time reverse transcription-PCR amplification was done by using a Premix Ex Taq and Smart Cyder system (Takara Bio, Inc.) according to the manufacturer's instructions. The following primers were used: FGFR2 (IIIb), forward 5-GATAAATAGTTCCAATGCAGAAGTCT-3 and reverse 5-TGCCCTATATAATTGGAGACCTTACA-3 (7); FGFR2 (COOH-terminal), forward 5-GAATACTGGACCTCAGCCAA-3 and reverse 5-AACACTGCCGTTATGTGTGG-3; and human-specific β -actin, forward 5-GGAAATCGTCCGTGACATT-3 and reverse 5-CATCTGCTGGAAGGTGGACAG-3. The experiment was independently done in triplicate using β -actin as a reference to normalize the data.

Western blotting. Cells were cultured overnight in 10% serum-containing medium or serum-starved medium and exposed to 0.1 to 10 μ mol/L of AZD2171 for 3 h before addition of KGF (100 ng/mL) for 15 min. Immunoblotting was done as described previously (14). In brief, after lysing the cells in radioimmunoprecipitation buffer, the lysate was electrophoresed through 10% (w/v) polyacrylamide gels. The proteins were transferred to polyvinylidene difluoride membranes and reacted with the following antibodies: anti-FGFR2 (H-80) and anti-FGFR2 (C-17) antibody (Santa Cruz Biotechnology, Inc.); anti-

phosphotyrosine antibody PY20 (BD Transduction Laboratories); anti-phosphorylated FGFR (Tyr653/654), anti-mitogen-activated protein kinase, anti-phosphorylated mitogen-activated protein kinase antibody, anti-AKT, anti-phosphorylated AKT, and anti-rabbit horseradish peroxidase-conjugated antibody (Cell Signaling Technology); and anti- β -actin antibody (Sigma). Visualization was achieved with an enhanced chemiluminescent detection reagent (Amersham Bioscience).

FGFR2 kinase assay. FGFR2/KGFR kinase activity was quantified by using a Universal Tyrosine Kinase Assay kit (Takara) according to manufacturer's instructions. FGFR2/KGFR proteins were collected from the KATO-III, OCUM2M, and OKAJIMA cell lysates by overnight immunoprecipitation with an anti-FGFR2 antibody. The FGFR2/KGFR immune complexes were washed thrice with radioimmunoprecipitation assay buffer and diluted kinase reaction buffer. Immobilized tyrosine kinase substrate (poly[Glu-Tyr]) was incubated for 30 min at 37°C with each sample in the presence of kinase-reacting solution and ATP. Samples were washed four times, blocked with blocking solution, and incubated with anti-phosphotyrosine antibody (PY20) conjugated to horseradish peroxidase. The absorbance of the phosphorylated substrate was measured at 450 nm.

Chemical cross-link analysis. The chemical cross-link analysis was carried out as described previously (15). In brief, KATO-III cells and OKAJIMA cells were cultured under serum-starved conditions for 24 h, and after stimulation with KGF (100 ng/mL) for 15 min, they were collected and washed with PBS and incubated for 30 min in PBS




Fig. 2. *A*, schematic representation of FGFR2 and regions amplified by PCR. *B*, mRNA expression levels of FGFR2 were quantified by detecting the extracellular domain or COOH-terminal region by real-time reverse transcription-PCR. Expression in the cells is shown as a ratio to expression in OKAJIMA cells. FGFR2 was overexpressed in KATO-III cells and OCUM2M cells by about 100-fold compared with the other cell lines. The majority of the FGFR2 in the sensitive cell lines KATO-III and OCUM2M had no COOH-terminal region. *C*, protein expression levels of FGFR2 were determined by Western blotting with antibodies to the NH₂ or COOH termini. Both AZD2171-sensitive cell lines overexpressed FGFR2, and the phosphorylation levels were markedly higher. *D*, chemical cross-linking analysis. Cells were cultured under serum-starved conditions for 24 h and then stimulated with KGF (100 ng/mL) for 15 min. After collecting and washing them with PBS, they were incubated for 30 min in PBS containing cross-linker substrate. The reaction was terminated by adding 250 mmol/L glycine for 5 min. In spite of the serum-starved conditions, high levels of expression of the dimerized form were observed in KATO-III cells in the absence of ligand stimulation. This phenomenon was not observed in the control undifferentiated OKAJIMA cell line. Ligand stimulation resulted in a mild increase in the dimerized form in KATO-III cells. Arrows indicate monomer or dimer formation.

containing 1.5 mmol/L of the non-permeable cross-linker bis-(sulfo-succinimidyl) substrate (Pierce). The reaction was terminated by adding 250 mmol/L glycine for 5 min, and the cells were analyzed by immunoblotting with FGFR2 antibody (Sigma).

FGFR2/KGFR gene silencing with small interfering RNA. Pre-designed small interfering RNA (siRNA) targeting FGFR2 was purchased from Ambion. KATO-III cells were plated on a 96-well plate and incubated in serum-containing medium for 24 h. The cells were then transfected with the FGFR2 targeting siRNA or non-silencing siRNA using RNAiFect Transfection Reagent (Qiagen) according to the

manufacturer's protocol and incubated another 72 h. Cell growth was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. For immunoblotting, 2×10^5 cells per well were plated on a six-well plate for 24 h and transfected with siRNA under the same conditions.

In vivo experiments. Tumorigenic TU-kato-III cells were derived from the gastric cancer cell line KATO-III. Four-week-old female BALB/c nude mice were purchased from CLEA Japan, Inc. and maintained under specific-pathogen-free conditions; 5×10^6 TU-kato-III cells or OCUM2M cells were s.c. injected into both flanks of each mouse. When the tumors had reached a volume of 0.1-0.3 cm³, the mice were randomized into three groups (three per group) and given AZD2171, 1.5 or 6.0 mg/kg/d, or vehicle once daily by oral gavage for 3 weeks. Tumor volume was calculated using the formula: (length \times width) \times $\sqrt{(\text{length} \times \text{width}) \times (\pi/6)}$, where length is the longest diameter across the tumor, and width is the corresponding perpendicular. All mice were sacrificed on day 21, and the tumors were collected. The protocol of the experiment was approved by the Committee for Ethics in Animal Experimentation and conducted in accordance with the Guidelines for Animal Experiments of National Cancer Center.




Fig. 3. A, FGFR2 targeting siRNA and cellular growth-inhibitory effect. KATO-III cells were plated on a 96-well plate and incubated in serum-containing medium for 24 h. After incubation, the cells were transfected with FGFR2-targeting or non-silencing siRNA and incubated for another 72 h. Cell growth was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. For immunoblotting, 2×10^5 cells per well were plated on a six-well plate and treated similarly. Marked inhibition of cell growth ($\sim 80\%$) was observed by FGFR2 targeting siRNA compared with control siRNA (top). Reduction of FGFR2 protein expression in KATO-III cells was confirmed by immunoblotting (bottom). Columns, % control absorbance in three independent experiments; bars, SD. B, Western blotting for downstream molecules of FGFR2 signaling. Cells were cultured overnight under serum-starved conditions and exposed to 0.1 to 10 $\mu\text{mol/L}$ AZD2171 for 3 h before adding 100 ng/mL KGF for 15 min. AZD2171 completely inhibited KGF-induced phosphorylation of FGFR2 at 1 $\mu\text{mol/L}$ in the sensitive cell lines, compared with 10 $\mu\text{mol/L}$ in the control cell line OKAJIMA. Similar results were observed for FRS-2, AKT, and mitogen-activated protein kinase (MAPK).

Results

AZD2171 showed growth-inhibitory activity in vitro. To evaluate the growth-inhibitory activity of AZD2171 *in vitro*, we did 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays on eight gastric cancer cell lines. The epidermal growth factor receptor-specific tyrosine kinase inhibitor gefitinib was used as a reference. The IC₅₀ of gefitinib for all cell lines was between 7 and 20 $\mu\text{mol/L}$. AZD2171 inhibited the growth of KATO-III cells and OCUM2M cells (IC₅₀, 0.15 and 0.37 $\mu\text{mol/L}$, respectively) more potently than the other cell lines (Fig. 1A).

Expression levels of tyrosine kinase receptors. To elucidate the mechanism of action of AZD2171 in the two sensitive cell lines, we measured mRNA expression levels of VEGFRs, FGFRs, and c-KIT, whose kinase activity have been reported to be inhibited by AZD2171 (10). No mRNA expression of VEGFRs or c-KIT was detected by reverse transcription-PCR in either sensitive cell lines. FGFR2 transcripts, however, were strongly expressed in both sensitive cell lines but not strongly in the other cell lines (Fig. 1B). Since we previously found that FGFR2/KGFR/K-sam with a deletion of COOH-terminal exons was amplified in both sensitive cell lines (9), we speculated that amplified FGFR2/KGFR might be associated with sensitivity to AZD2171.

Sensitive cells expressed constitutively active and spontaneously dimerized FGFR2/KGFR. We quantified mRNA expression levels of FGFR2 by real-time reverse transcription-PCR with primers that detect the extracellular domain (IIIb region, see Fig. 2A) and COOH-terminal region. The results show that KATO-III cells and OCUM2M cells expressed FGFR2 100-fold higher than the other cells tested. The COOH-terminal region of FGFR2 was deleted in the KATO-III cells and OCUM2M cells (Fig. 2B). Overexpression and markedly increased phosphorylation of FGFR2 was observed in the AZD2171-sensitive cell lines (Fig. 2C).

Immunoblotting with antibodies for the COOH and NH₂ termini revealed that almost all the FGFR2 expressed by OCUM2M cells, and about half of FGFR2 expressed by KATO-III cells, were truncated (Fig. 2C). Although the KATO-III cells expressed wild-type receptor to some extent, the

Table 1. *In vitro* kinase assay of AZD2171 against FGFR2

Cell line	K_m	K_i ($\mu\text{mol/L}$)
KATO-III	8.3 ± 3.3	0.067 ± 0.017
OCUM2M	7.1 ± 1.4	0.072 ± 0.022
OKAJIMA	11.0 ± 5.0	0.049 ± 0.041

COOH-terminal truncated type was dominantly expressed in AZD2171-sensitive cell lines.

A chemical cross-linking analysis was done to evaluate the dimerization of FGFR2. High dimerization of FGFR2 was observed in the KATO-III cells even in the absence of ligand stimulation (Fig. 2D), but no such phenomenon was observed in the control undifferentiated OKAJIMA cell line. Ligand stimulation increased the level of the dimerized-form in KATO-III cells. Taken together, these findings show that the sensitive cell lines expressed high levels of FGFR2 that was highly phosphorylated and spontaneously dimerized without ligand stimulation, suggesting that FGFR2 signaling is constitutively activated in these cells. This evidence is consistent with the widely recognized findings that cancer cells sensitive to other tyrosine kinase inhibitors, such as gefitinib and imatinib, overexpress the highly phosphorylated target receptor with an increased level of dimerization in a ligand-independent manner (12, 16, 17).


FGFR2 targeting siRNA showed a potent growth-inhibitory effect on KATO-III cells. To investigate the dependency of cell

growth through activated FGFR2 signaling in the AZD2171-sensitive KATO-III cell line, we evaluated the growth-inhibitory effect of siRNA targeted to FGFR2 in KATO-III cells. Targeted siRNA (5-100 nmol/L) decreased FGFR2 and inhibited cell growth (>80%) in a dose-dependent manner (Fig. 3A). The results show that most of the growth of KATO-III cells is dependent on activated FGFR2 signaling, suggesting that the FGFR signaling dependency may be responsible for the higher growth-inhibitory effect of AZD2171 on KATO-III cells.

AZD2171 inhibited FGFR2 signaling. Next, we examined the effect of AZD2171 on FGFR2 downstream phosphorylation signals (i.e., FRS-2, AKT, and mitogen-activated protein kinase). AZD2171 completely inhibited KGF-induced phosphorylation of FGFR2, FRS-2, AKT, and mitogen-activated protein kinase at 1 $\mu\text{mol/L}$ in KATO-III cells, compared with 10 $\mu\text{mol/L}$ in OKAJIMA cells. These results clearly show that AZD2171 possesses inhibitory activity against FGFR2 in cell-based studies and significantly inhibits the phosphorylation of FGFR2 at 1 $\mu\text{mol/L}$ in sensitive cells.

FGFR2 kinase inhibition of AZD2171. To quantify the inhibitory activity of AZD2171 on FGFR2 kinase under cell-free conditions, we calculated the K_i values for immunoprecipitated FGFR2 derived from KATO-III, OCUM2M, and OKAJIMA cells. The K_i values of AZD2171 for FGFR2 in each of these cell lines were 0.067 ± 0.017 , 0.072 ± 0.022 , and 0.049 ± 0.041 $\mu\text{mol/L}$, respectively (Table 1). In contrast, the K_i value of AZD2171 for recombinant VEGFR-2 was 0.0009 $\mu\text{mol/L}$ (data not shown) and was consistent with previous reports (10). At the cellular level, phosphorylation of

Fig. 4. A, *in vivo* growth-inhibitory effect of AZD2171 in a tumor xenograft model. After s.c. injecting 5×10^6 TU-kato-III or OCUM2M cells into both flanks of the mice, AZD2171 (1.5 or 6.0 mg/kg/d), or vehicle, was administered orally once daily for 3 wks. A marked tumor growth-inhibitory effect was observed at the low dose (1.5 mg/kg/d) of AZD2171 in both the TU-kato-III tumors and OCUM2M tumors, and the high dose (6.0 mg/kg/d) of AZD2171 completely inhibited the growth of both cell lines. **B, representative H&E staining of tumor tissue from mice treated with AZD2171.** Broad dose-dependent necrosis was observed. Original magnification, $\times 40$.



FGFR2 was inhibited at 10-fold lower concentrations of AZD2171 in the sensitive cell lines (Fig. 3B), but there were no marked differences between the kinase-inhibitory effects among the proteins derived from the cell lines in this cell-free assay. This discrepancy is discussed in the Discussion.

In vivo antitumor activity of AZD2171 against FGFR2-overexpressing gastric cancer. To elucidate the *in vivo* antitumor activity of AZD2171 in mice bearing gastric cancer tumor xenografts, we used the newly established tumorigenic subline TU-kato-III (derived from KATO-III) and OCCUM2M. We attempted to perform control experiments using OKAJIMA cells *in vivo* as suggested by the reviewer. Unfortunately, however, the cell lines grew slowly in the mice, and we could not precisely evaluate the antitumor activity of AZD2171 in the model. However, the results of preliminary experiments showed that AZD2171 seemed to be less effective against OKAJIMA cells than against KatoIII and OCUM2M cell *in vivo*. Mice implanted the TU-kato-III and OCUM2M tumors were given a low or high dose of AZD2171 (i.e., 1.5 or 6.0 mg/kg/d), or vehicle, orally for 3 weeks. AZD2171 (1.5 mg/kg/d) significantly inhibited tumor growth in the mice bearing TU-kato-III and OCUM2M tumors, and the higher dose (6.0 mg/kg/d) completely inhibited the growth of both tumor models (Fig. 4A). H&E staining showed broad dose-dependent necrosis of core tumor tissue in mice treated with AZD2171 (Fig. 4B). Thus, AZD2171 showed marked antitumor activity *in vivo* against both human gastric tumor xenografts.

Discussion

Recent studies have shown that FGFRs and their ligands are promising therapeutic target molecules for various malignant diseases, such as prostate cancer (18), breast cancer (5, 19), endometrial carcinoma (20), synovial sarcomas (21), thyroid carcinoma (22, 23), and hematopoietic malignancies (24–27). These findings are based on the biological properties of malignant cells expressing activated FGFR, like FGFR fusion tyrosine kinase, involved in chromosomal translocations, gene amplification of FGFRs, or overexpression of FGFs (5, 18–27). In the case of gastric cancer, the results of immunohistochemical analysis of clinical samples revealed that 20 of 38 cases of advanced undifferentiated type of gastric cancer were FGFR2/K-sam positive, whereas none of the 11 cases with the differentiated or intestinal type of cancer showed positive staining for K-sam (8). The results suggest that FGFR2/K-sam overexpression is associated with the undifferentiated type of stomach

cancers. The results of fluorescence *in situ* hybridization analysis of the gastric cancer specimens showed gene amplification of FGFR2/K-sam in 2.9% (28). The clinical implication of FGFR2 overexpression/amplification in gastric cancers remains to be fully clarified, and further investigation is needed.

AZD2171 has the most potent kinase-inhibitory activity against VEGFR-2 ($IC_{50} < 1$ nmol/L); it also possesses additional activity against VEGFR-1, VEGFR-3, and c-Kit (IC_{50} , 5, ≤ 3 , and 2 nmol/L, respectively; ref. 10). AZD2171 showed antiangiogenic activity and broad antitumor activity consistent with potent inhibition of VEGF-induced angiogenesis. We showed kinase-inhibitory activity of AZD2171 against FGFR2 in the present study. When cancer cells are dependent on FGFR2 signaling, AZD2171 can be expected to give additional therapeutic benefit in addition to its antiangiogenic effects.

A cell-based Western blotting analysis showed that phosphorylation of FGFR2 in KATO-III cells and OCUM2M cells was inhibited by AZD2171 at 10-fold lower dose than in OKAJIMA cells (Fig. 3B). However, there was no significant difference in the K_i values of AZD2171 between the FGFR2 derived from KATO-III, OCUM2M, and OKAJIMA in an *in vitro* kinase assay. This may be attributable to the different conditions between the cell-based and cell-free assays. For example, undefined intrinsic intracellular factors may influence kinase activity: (a) differences in baseline intracellular FGFR2 phosphatase activity in each cell line, (b) differences in intracellular concentration of (transporters, such as ATP-binding cassette transporters, may be involved in this phenomenon refs. 29, 30), and (c) undefined intrinsic inhibitory factors that bind the compounds directly may also be involved (e.g., Brehmer D, et al. have identified various gefitinib binding proteins by affinity chromatography; ref. 31).

In conclusion, AZD2171, a potent inhibitor of all VEGFRs (VEGFR-1, VEGFR-2, and VEGFR-3), was found to have antitumor effect against gastric cancer xenografts in line with previous findings in colon, lung, prostate, breast, and ovarian tumor xenografts (10). The results of this study suggest that activation of the FGFR2 pathway may be a promising target for gastric cancer therapy. AZD2171 may provide a clinical benefit to gastric cancer patients.

Acknowledgments

We thank Dr. T. Komatsu and M. Takigahira for the animal study and Dr. K. Hirakawa (Osaka City University Graduate School of Medicine, Osaka, Japan) for providing the OCUM2M cell line.

References

1. Vanhoef U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. *J Clin Oncol* 2000;18:2:648–57.
2. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* 2003;21:54–9.
3. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. *Cytokine Growth Factor Rev* 2005;16:179–86.
4. Itoh H, Hattori Y, Sakamoto H, et al. Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. *Cancer Res* 1994;54:3237–41.
5. Moffa AB, Tannheimer SL, Ethier SP. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. *Mol Cancer Res* 2004;2:643–52.
6. Nakatani H, Sakamoto H, Yoshida T, et al. Isolation of an amplified DNA sequence in stomach cancer. *Jpn J Cancer Res* 1990;81:707–10.
7. Hattori Y, Odagiri H, Nakatani H, et al. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. *Proc Natl Acad Sci U S A* 1990;87:5983–7.
8. Hattori Y, Itoh H, Uchino S, et al. Immunohistochemical detection of K-sam protein in stomach cancer. *Clin Cancer Res* 1996;2:1373–81.
9. Ueda T, Sasaki H, Kuwahara Y, et al. Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. *Cancer Res* 1999;59:6080–6.
10. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular

- endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. *Cancer Res* 2005;65:4389–400.
11. Arao T, Yanagihara K, Takigahira M, et al. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. *Int J Cancer* 2006;118:483–9.
 12. Arao T, Fukumoto H, Takeda M, et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. *Cancer Res* 2004;64:9101–4.
 13. Taguchi F, Koh Y, Koizumi F, et al. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. *Cancer Sci* 2004;95:984–9.
 14. Koizumi F, Kanzawa F, Ueda Y, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. *Int J Cancer* 2004;108:464–72.
 15. Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. *Int J Cancer* 2005;116:36–44.
 16. Sakai K, Arao T, Shimoyama T, et al. Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor. *FASEB J* 2006;20:311–3.17. Duensing A, Heinrich MC, Fletcher CD, Fletcher JA. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. *Cancer Invest* 2004;22:106–16.
 18. Gowardhan B, Douglas DA, Mathers ME, et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. *Br J Cancer* 2005;92:320–7.
 19. Zang XP, Nguyen TN, Pento JT. Specific and non-specific KGF inhibition of KGF-induced breast cancer cell motility. *Anticancer Res* 2002;22:2539–45.
 20. Taniguchi F, Harada T, Sakamoto Y, et al. Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. *J Clin Endocrinol Metab* 2003;88:773–80.
 21. Ishibe T, Nakayama T, Okamoto T, et al. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. *Clin Cancer Res* 2005;11:2702–12.
 22. St Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. *Endocrinology* 2005;146:1145–53.
 23. Ezzat S, Huang P, Dackiw A, Asa SL. Clin Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. *Cancer Res* 2005;11:1336–41.
 24. Chen J, Lee BH, Williams IR, et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. *Oncogene* 2005;24:8259–67.
 25. Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. *Blood* 2005;105:2941–8.
 26. Delaval B, Letard S, Lelievre H, et al. Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome. *Cancer Res* 2005;65:7231–40.
 27. Chen J, Deangelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. *Proc Natl Acad Sci U S A* 2004;101:14479–84.
 28. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence *in situ* hybridization. *Lab Invest* 1998;9:43–53.
 29. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. *Mol Cancer Ther* 2004;3:1119–25.
 30. Elkind NB, Szentpetery Z, Apati A, et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). *Cancer Res* 2005;65:1770–7.
 31. Brehmer D, Greff Z, Godl K, et al. Cellular targets of gefitinib. *Cancer Res* 2005;65:379–82.

